NEWS
Updated Phase 2 OraGrowtH Data Presented at ESPE 2024 Demonstrate Sustained Growth on Oral LUM-201 to 24 Months in PGHD and Correlation of Growth to LUM-201’s Unique Pulsatile Mechanism of Action
Lumos Pharma presented new analyses from Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials at ESPE 2024. The data showed sustained growth on LUM-201 in moderate Pediatric Growth Hormone Deficiency (PGHD) patients over 24 months. Results demonstrated significant increases in Annualized Height Velocity (AHV) from baseline 4.6 cm/yr to 7.8 cm/yr at 6 months, maintaining 7.3 cm/yr at 24 months. The studies also showed notable improvements in IGF-1 levels from 13.1 to 29.2 nmol/L and IGFBP-3 from 133.5 to 186.2 nmol/L over 24 months. Additional analysis revealed correlation between pulsatile growth hormone secretion patterns and growth responses to LUM-201 treatment.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2538Followers
107Following
28KVisitors
Follow